

# ICPO Theranostics FAP Summit

## Targeting the Tumor Microenvironment and Beyond

Friday 4 & Saturday 5 November 2022



### PRELIMINARY PROGRAMME

Subject to change | Revision Sep 20, 2022 | All stated times correspond to Central European Time

**FRIDAY, 4 NOVEMBER 2022**

**What is FAP? History of FAP - Diagnostics using FAP - FAP Innovation & FAP PET Reading**

16:00 – 16:10 CET	<b>Welcome by SAB Chairman and ICPO</b>
----------------------	---

#### SESSION I: Introduction to FAP

16:10 – 16:25 CET	<b>What is FAP? Genesis to today</b> Andrew Scott, Australia
16:25 – 16:40 CET	<b>LRRC15 - a TGFB-driven FAP-like protein</b> David Ulmert, USA
16:40 – 16:55 CET	<b>FAP in Tumor micro environment, Molecular Pathology Perspective</b> Ralph Wirtz, Germany
16:55 – 17:10 CET	<b>Pharmacologic targeting of master regulators of the tumor microenvironment</b> Andrea Califano, USA

#### SESSION II: Diagnostics for Oncology

17:15 – 17:30 CET	<b>FAPi PET Next Wave of Molecular Imaging</b> Frederik L. Giesel, Germany
17:30 – 17:45 CET	<b>FAPi is not the new FDG</b> Jeremie Calais, USA
17:45 – 18:00 CET	<b>FAPi in FDG negative / low metabolic tumors</b> Andrea Farolfi, Italy and USA
18:05 – 18:15	<b>Break</b>

#### SESSION III: Diagnostics for Non-Oncology

18:15 – 18:30 CET	<b>Cardiac applications of FAPi PET</b> Johanna Diekmann, Germany
18:30 – 18:45 CET	<b>FAP imaging in immune-mediated inflammatory diseases</b> Christian Schmidkonz, Germany
18:45 – 19:00 CET	<b>Liver fibrosis and fibrogenesis</b> Ali Pirasteh, USA
19:00 – 19:15 CET	<b>Use of FAPi PET for targeted biopsy target and in endovascular treatment</b> N. N.

# ICPO Theranostics FAP Summit

## Targeting the Tumor Microenvironment and Beyond

Friday 4 & Saturday 5 November 2022



### FRIDAY, 4 NOVEMBER 2022

#### What is FAP? History of FAP - Diagnostics using FAP - FAP Innovation & FAP PET Reading

##### PANEL I: FAP DIAGNOSTIC

19:20 – 20:20 **Clinical utility and outperformance of FAPi diagnostic**  
CET Moderator: Ken Herrmann, Germany

20:20 – 20:30 **Break**  
CET

##### SESSION IV: Preclinical & Chemistry, Emerging Theranostics

20:30 – 20:45 **FAP-inhibitors and substrates: a medicinal chemistry perspective**  
CET Pieter van der Veken, Belgium

20:45 – 21:00 **Development of FAP ligands and clinical transfer**  
CET Uwe Haberkorn, Germany

21:00 – 21:15 **FAP ligands and its challenges in Theranostics**  
CET Frank Rösch, Germany

##### PANEL II: FAP INNOVATION

21:20 – 22:00 **FAP as a biomarker, exploration of radionuclide labeling utility for FAP compounds**  
CET Moderator: Klaus Klopka, Germany

##### BONUS

22:00 – 22:30 **Presentations of Clinically Interesting FAP PET Cases**  
CET Moderator: Sze Ting Lee, Australia

# ICPO Theranostics FAP Summit

## Targeting the Tumor Microenvironment and Beyond

Friday 4 & Saturday 5 November 2022



### SATURDAY, 5 NOVEMBER 2022

#### FAP Therapy Innovation and Clinical Profile - FAP in clinical trials – Patient Access and Global Perspective

16:00 – 16:10 **Welcome by SAB Chairman and ICPO**  
CET

#### **SESSION V:** Innovation in Radioligand Therapeutics

16:10 – 16:25 **How to develop FAP ligands**  
CET John Babich, USA

16:25 – 16:40 **Evans blue modified FAPI (EB-FAPI) developed by Yantai LNC Biotech**  
CET Shawn Chen, Singapore

16:40 – 16:55 **3B Pharma developments**  
CET Christiane Smerling, Germany

16:55 – 17:10 **Fibroblast activation protein-based theranostics in cancer research: Improvement in the FAPI probe and FAP-targeted radionuclide therapy**  
CET Haojun Chen, China

17:10 – 17:25 **FAP protein engineering developments**  
CET Navigo Proteins, Germany

#### **SESSION VI:** Non-Radioligand Therapeutics

17:30 – 17:45 **Pre-clinical Development of AVA6000 – a FAP targeted chemotherapeutic agent in Phase I**  
CET Fiona McLaughlin, United Kingdom

17:45 – 18:00 **TBA**  
CET N. N.

18:05 – 18:15 **Break**  
CET

#### **PANEL III:** FAP THERAPY

18:15 – 19:20 **How to raise the clinical profile of FAP Therapeutics? What is the impact of FAP on patient management in selected clinical cases**  
CET Moderator: Elcin Zan, USA

# ICPO Theranostics FAP Summit

## Targeting the Tumor Microenvironment and Beyond

Friday 4 & Saturday 5 November 2022



### SATURDAY, 5 NOVEMBER 2022

#### Therapy using FAP - FAP in clinical trials - Patient Access and regulatory - Ask the experts

##### SESSION VII: Clinical Trials, Emerging Therapeutics/Diagnostics

19:20 – 19:35 CET	<b>PTRT, FAP peptide targeted radioligand therapy: clinical experience in different adenocarcinomas</b> Richard P. Baum, Germany
19:35 – 19:50 CET	<b>FAPI clinical development updates by Sofie Biosciences</b> Sherly Mosessian, USA
19:50 – 20:05 CET	<b>177Lu-FAP-2286 in Patients with Advanced or Metastatic Solid Tumours: Updated Data From a Phase 1/2 Study Investigating Safety, Pharmacokinetics, Dosimetry, and Preliminary Antitumour Activity (LuMIERE)</b> Curt Wolfgang, USA
20:05 – 20:20 CET	<b>FRONTIER: A Phase 1 Theranostic Study of FAP-targeted [Lu-177]-PNT6555 in Patients with Select Solid Tumors</b> Richard Cioci, Canada
20:20 – 20:35 CET	<b>177Lu-DOTAGA-SA-FAPI-Dimer - New hope for Radioiodine Refractory metastatic differentiated Thyroid Cancer Patients</b> C.S. Bal, India
20:40 – 20:50 CET	<b>Break</b>

##### SESSION VIII: Patient access and future regulatory landscape, FAP Radiopharmaceuticals in a global perspective

20:50 – 21:05 CET	<b>Perspective on FAP Patient Access</b> Josh Mailman, USA
21:05 – 21:20 CET	<b>Current status and future perspective in Japan</b> Tadashi Watabe, Japan
21:20 – 21:35 CET	<b>FAP targeting radiopharmaceuticals in Latin America: Current state and future perspective</b> Vasko Kramer, Chile
21:35 – 21:50 CET	<b>African perspective</b> Mike Sathekge, South Africa

##### PANEL IV: ROUNDTABLE

21:55 – 22:25 CET	<b>On Future Outlook on FAP</b> Moderator: Frederik Giesel, Germany
----------------------	--

##### CLOSING

22:25 – 22:30 CET	<b>Closing words by SAB Chairman and ICPO</b>
----------------------	---